ImmunityBio (NASDAQ:IBRX) Earns “Buy” Rating from D. Boral Capital
ImmunityBio (NASDAQ:IBRX – Get Free Report)‘s stock had its “buy” rating restated by D. Boral Capital in a research note issued to investors on Tuesday,Benzinga reports. They presently have a $30.00 price objective on the stock. IBRX has been the topic of several other research reports. HC Wainwright restated a “buy” rating and set a […]
ImmunityBio (NASDAQ:IBRX – Get Free Report)‘s stock had its “buy” rating restated by D. Boral Capital in a research note issued to investors on Tuesday,Benzinga reports. They presently have a $30.00 price objective on the stock. IBRX has been the topic of several other research reports. HC Wainwright restated a “buy” rating and set a […]
